WCLC 2023 | Updates in upfront systemic therapy for ES-SCLC

Misty Shields, MD, PhD, Indiana University, Bloomington, IN, discusses the latest updates in upfront systemic therapy for extensive-stage small cell lung cancer (ES-SCLC). New data for 5-year patient survival in the Impower133 trial (NCT02763579) demonstrated the benefit of after upfront systemic therapy in ES-SCLC. Dr Shields comments on recent publications that highlight the cost-effectiveness and efficacy of upfront therapy with chemoimmunotherapy for supportive care. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.